The fifth case is a key milestone in the study because a data safety monitoring board will be able to review the SynerFuse concept, according to a July 26 news release.
“We’re one step closer to demonstrating the viability of our non-narcotic solution for spinal fusion patients with chronic lower back pain,” SynerFuse CEO Justin Zenanko said in the release.
The combination procedure adds a neurostimulator to stimulate the dorsal root ganglion to provide relief to patients with back pain. The study will enroll up to 20 patients, the release said.